Progyny, Inc. (PGNY)
| Market Cap | 1.42B -26.1% |
| Revenue (ttm) | 1.29B +10.4% |
| Net Income | 58.52M +7.7% |
| EPS | 0.65 +14.0% |
| Shares Out | 78.33M |
| PE Ratio | 27.95 |
| Forward PE | 9.61 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,439,909 |
| Open | 17.72 |
| Previous Close | 17.67 |
| Day's Range | 17.57 - 18.19 |
| 52-Week Range | 16.10 - 28.75 |
| Beta | 0.99 |
| Analysts | Buy |
| Price Target | 26.50 (+45.85%) |
| Earnings Date | May 7, 2026 |
About PGNY
Progyny, Inc., a benefits management company, provides fertility, family building, and women’s health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management s... [Read more]
Financial Performance
In 2025, Progyny's revenue was $1.29 billion, an increase of 10.40% compared to the previous year's $1.17 billion. Earnings were $58.52 million, an increase of 7.70%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for PGNY stock is "Buy." The 12-month stock price target is $26.5, which is an increase of 45.85% from the latest price.
News
Progyny, Inc. Announces Details for Its First Quarter 2026 Results Report
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period e...
Progyny Expands Access to Fertility and Women's Health with Industry's First Fully Insured Supplemental Plan
NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announces Progyny Select, the industry's first fully i...
Progyny Commemorates 10 Years of Redefining Women's Health and Family Building Care
Throughout 2026, in partnership with members, providers, and employers, Progyny will highlight a decade of innovation, expanded access, and industry-leading outcomes. Throughout 2026, in partnership w...
Progyny Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Administrative adjustments led to a reduction in eligible lives, but utilization rates remain strong and stable. The new fully insured product targets small employers, with risk managed through data-d...
Progyny Transcript: Barclays 28th Annual Global Healthcare Conference
Strong client retention, stable utilization, and expanded offerings position the business for continued growth. New products target unmet needs in the fully insured market, with positive early feedbac...
Progyny Transcript: Leerink Global Healthcare Conference 2026
Utilization and consumption remained stable in 2025, with growth driven by new members and consistent treatment patterns. Strategic investments in IT, product expansion into menopause and benefit navi...
Progyny, Inc. Executives to Participate in Upcoming Investor Conferences
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that several members of its leadership team ...
Progyny Earnings Call Transcript: Q4 2025
Record 2025 results with double-digit revenue and adjusted EBITDA growth, strong cash flow, and near 100% client retention. 2026 guidance projects continued growth, margin expansion, and lower stock-b...
Progyny, Inc. Announces Fourth Quarter 2025 Results
Reports Revenue of $318.4 Million, Reflecting Fourth Quarter Growth of 6.7% and 10% for the Full YearGenerated Record $210.2 Million in Full Year Operating Cash FlowReturned Value to Shareholders Thro...
Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2025 Results Report
NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period an...
Progyny Transcript: 44th Annual J.P. Morgan Healthcare Conference
Client retention remains near 100% with 900,000 new lives added, and new services and global expansion are underway. Progyny Select targets small employers, expanding the addressable market by 50 mill...
Progyny to Discuss Updated Financial Expectations at Upcoming JP Morgan Healthcare Conference
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today announced that the Company...
New Men's Health Research from Progyny Challenges Conventional Beliefs about Fertility Knowledge and Action
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in family building solutions, today announced new men's health research exploring experiences and views on fer...
Does Progyny Stock Lead The Pack?
Progyny is a leader in fertility benefits, offering employers comprehensive, outcomes-based solutions that improve treatment success and manage costs. Its focused model has driven strong demand and se...
Progyny Transcript: Jefferies London Healthcare Conference 2025
The company leads the U.S. fertility benefits market, with stable utilization and high client retention. Growth is driven by new product launches, expansion into smaller employer markets, and supporti...
Progyny, Inc. to Present at Jefferies Global Healthcare Conference
NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that Mark Livingston, Progyny's Chief Financi...
Progyny Earnings Call Transcript: Q3 2025
Third quarter revenue and profitability exceeded guidance, prompting a full-year outlook raise. Strong client retention, new product launches, and a $200M share repurchase program highlight continued ...
Progyny, Inc. Announces Third Quarter 2025 Results
Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and N...
Progyny, Inc. Announces Details for Its Third Quarter 2025 Results Report
NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period en...
Progyny Expands Global Benefits to Include Pregnancy, Postpartum, and Menopause
NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc . (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced the launch of its pregnancy, postpartum, and...
Progyny CEO Named World Economic Forum Champion for Women's Health
Progyny joins global leaders to accelerate advancement in research, innovation, and resilience in women's health Progyny joins global leaders to accelerate advancement in research, innovation, and res...
Progyny Earnings Call Transcript: Q2 2025
Q2 2025 saw record revenue and adjusted EBITDA, with strong growth in core business and gross margin expansion. Full-year guidance was raised, supported by robust client demand, new product launches, ...
Progyny, Inc. Announces Second Quarter 2025 Results
Reports Record Revenue of $332.9 Million, Reflecting 9.5% GrowthGenerates $55.5 Million in Quarterly Operating Cash Flow and Record $105.3 Million over the First Half of 2025 Raises Full Year Guidance...
New Progyny Study Reveals Gap Between Perceptions and Realities in Women's Health Benefits Coverage
Increased awareness of expanded women's health and family building solutions has led to a growing disconnect between most wanted employee benefits and employer offerings Increased awareness of expande...
Progyny Partners with ŌURA to Empower Women and Their Care Teams with Wearable Tech Data, Further Supporting Outcomes from Preconception to Menopause
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced a new partnership with ŌURA , maker of the wo...